Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Euler, Zelda ^a   van Gils, Marit J ^a   Boeser Nunnink, Brigitte D ^a   Schuitemaker, Hanneke ^a,b   van Manen, Daniëlle ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; PROTEIN HCP5; PROTEIN MICA; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NETHERLANDS; NONHUMAN; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CD4 LYMPHOCYTE COUNT; CLUSTER ANALYSIS; GENETICS; HOMOSEXUALITY; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; CD4 LYMPHOCYTE COUNT; CLUSTER ANALYSIS; CROSS REACTIONS; GENOME-WIDE ASSOCIATION STUDY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HOMOSEXUALITY; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; VIRAL LOAD;

EID: 84872817036     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054684     Document Type: Article

References (35)

1. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84: 1631-1636.
2. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, et al. (2010) Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 201: 1045-1053.
3. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) HIV-1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified Using a High Throughput Neutralization Assay Together with an Analytical Selection Algorithm. J Virol 83: 7337-7348.
4. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.
5. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951-954.
6. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84.
7. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H, (2009) Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23: 2405-2414.
8. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, et al. (2012) HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85: 4828-4840.
9. Pulendran B, Ahmed R, (2011) Immunological mechanisms of vaccination. Nat Immunol 12: 509-517.
10. Gelder CM, Lambkin R, Hart KW, Fleming D, Williams OM, et al. (2002) Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 185: 114-117.
11. Van Griensven GJP, De Vroome EMM, Goudsmit J, Coutinho RA, (1989) Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. Br Med J 298: 218-221.
12. De Roda Husman AM, Koot M, Cornelissen M, Brouwer M, Broersen SM, et al. (1997) Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 127: 882-890.
13. Centers for disease control (1993) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41 (RR-17): 1-19.
14. van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, Van 't Wout AB, et al. (2009) Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 23: 19-28.
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
16. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944-947.
17. Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, et al. (2009) Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). J Infect Dis 200: 1194-1201.
18. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, et al. (2009) Common genetic variation and the control of HIV-1 in humans. PLoS Genet 5: e1000791.
19. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, et al. (2008) Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS ONE 3: e3907.
20. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551-1557.
21. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, et al. (2009) Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 199: 419-426.
22. Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, et al. (2000) Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 62: 14-24.
23. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, et al. (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 82: 11651-11668.
24. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, et al. (2011) Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1. PLoS Pathog 7: e1001251.
25. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83: 757-769.
26. Medina-Ramirez M, Sanchez-Merino V, Sanchez-Palomino S, Merino-Mansilla A, Ferreira CB, et al. (2011) Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol 85: 5804-5813.
27. Champsaur M, Lanier LL, (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235: 267-285.
28. Norman JM, Mashiba M, McNamara LA, Onafuwa-Nuga A, Chiari-Fort E, et al. (2011) The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol 12: 975-983.
29. Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA, (2010) HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 115: 1354-1363.
30. Nolting A, Dugast AS, Rihn S, Luteijn R, Carrington MF, et al. (2010) MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology 406: 12-20.
31. Maloy KJ, Odermatt B, Hengartner H, Zinkernagel RM, (1998) Interferon gamma-producing gammadelta T cell-dependent antibody isotype switching in the absence of germinal center formation during virus infection. Proc Natl Acad Sci U S A 95: 1160-1165.
32. Juleff N, Windsor M, Lefevre EA, Gubbins S, Hamblin P, et al. (2009) Foot-and-mouth disease virus can induce a specific and rapid CD4+ T-cell-independent neutralizing and isotype class-switched antibody response in naive cattle. J Virol 83: 3626-3636.
33. Mbow ML, Zeidner N, Gilmore RD Jr, Dolan M, Piesman J, et al. (2001) Major histocompatibility complex class II-independent generation of neutralizing antibodies against T-cell-dependent Borrelia burgdorferi antigens presented by dendritic cells: regulation by NK and gammadelta T cells. Infect Immun 69: 2407-2415.
34. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, et al. (2003) Advantage of rare HLA supertype in HIV disease progression. Nat Med 9: 928-935.
35. Paul P, van den Hoorn T, Jongsma MLM, Bakker MJ, Hengeveld R, et al. (2011) A Genome-wide Multidimensional RNAi Screen Reveals Pathways Controlling MHC Class II Antigen Presentation. Cell. In press.